TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2683908

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg administered sublingually)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 12
Study: 31855303

Group type: EXPERIMENTAL
Intervention: Methotrexate or azathioprine
Number of subjects: 38
Study: 29620663

Group type: EXPERIMENTAL
Intervention: Low sodium salt (LSSalt) diet
Number of subjects: 126

Group type: COMPARATOR
Intervention: Normal salt (NSalt) diet
Number of subjects: 126
Study: 28963313

Group type: EXPERIMENTAL
Intervention: e-learning
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: group training
Number of subjects: 247

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 247

Group type: COMPARATOR
Intervention: all groups
Number of subjects: 247
Study: 25194517

Group type: EXPERIMENTAL
Intervention: 3D navigational feedback on sawbones
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3D navigational feedback on cadavers
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 15
Study: 24517212

Group type: EXPERIMENTAL
Intervention: MTX + hydroxychloroquine + sulphasalazine + prednisone (arm 1)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: MTX + adalimumab (arm 2)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Early remission (DAS <1.6 after 4 months)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Early remission
Number of subjects: 610

Group type: COMPARATOR
Intervention: Patients not in early remission
Number of subjects: 610
Study: 21371496

Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 135
Study: 18717710

Group type: EXPERIMENTAL
Intervention: Classic ketogenic diet (KD) with glucose (60 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Classic ketogenic diet (KD) with saccharin
Number of subjects: 20
Study: 16958397

Group type: EXPERIMENTAL
Intervention: Self-expandable metallic stent placement
Number of subjects: 19
Study: 14698679

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) 100 microg bolus injection
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) 150 microg infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal saline infusion (control)
Number of subjects: 12
Study: 11085402

Group type: EXPERIMENTAL
Intervention: Canada411
Number of subjects: 346

Group type: COMPARATOR
Intervention: InfoSpace
Number of subjects: 346
Study: 8829056

Group type: EXPERIMENTAL
Intervention: Laparoscopic presacral neurectomy (LPSN)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Laparoscopic uterine nerve ablation (LUNA)
Number of subjects: 68
Study: 1573045

Group type: EXPERIMENTAL
Intervention: Buspirone 5 mg three times a day for the first week, then 10 mg in the morning, 5 mg in the afternoon, and 5 mg in the evening for the next three weeks.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg three times a day for all 4 weeks.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo during the first 7 days and the last 7 days of the study.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Driving performance test after each treatment week.
Number of subjects: 24
Study: 3993625

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (DTIC, DTIC/CCNU/vincristine)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no further treatment after surgery)
Number of subjects: 26
Study: 30981313

Group type: EXPERIMENTAL
Intervention: Fluralaner (Bravecto®)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20
Study: 29316912

Group type: EXPERIMENTAL
Intervention: Self-reported changes in sleep patterns (Pittsburgh Sleep Quality Index) from six weeks to seven months postpartum
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Self-reported changes in sleep latency, daytime dysfunction, and sleep quality
Number of subjects: 122
Study: 26638185

Group type: EXPERIMENTAL
Intervention: Intervention (obesity prevention intervention embedded in parenting program)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (weekly mailings)
Number of subjects: 56
Study: 23743209

Group type: COMPARATOR
Intervention: Propofol alone (group P, n=13)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 20% N2O and propofol (group N+P, n=13)
Number of subjects: 26
Study: 22693238

Group type: EXPERIMENTAL
Intervention: Caffeine (CAFF) 3 mg/kg body mass
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (SB) 0.3 g · kg⁻¹ · BM⁻¹
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine + Sodium Bicarbonate (CAFF+SB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 10
Study: 20022589

Group type: EXPERIMENTAL
Intervention: Corticosteroids (single course)
Number of subjects: 183
Study: 18332706

Group type: EXPERIMENTAL
Intervention: Amino acid infusion at 2.5-3.0 g/kg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amino acid infusion at 4.0 g/kg/day
Number of subjects: 0
Study: 16260639

Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clopidogrel 900 mg
Number of subjects: 60
Study: 12163796

Group type: EXPERIMENTAL
Intervention: Prone position for 6 hours for four consecutive days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonprone position
Number of subjects: 16
Study: 10381666

Group type: EXPERIMENTAL
Intervention: Corticosteroids (starting doses of 60-1000 mg per day, reduced to 40-50 mg per day after 4-6 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Corticosteroids (conventional dose 60-80 mg per day vs very high doses 200-1000 mg per day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Corticosteroids (various doses)
Number of subjects: 22
Study: 7594326

Group type: EXPERIMENTAL
Intervention: LPZ 30 mg and AMPC 1,500 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: LPZ 30 mg alone
Number of subjects: 40
Study: 2407766

Group type: EXPERIMENTAL
Intervention: Magnesium citrate (25 mmol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Magnesium oxide (25 mmol)
Number of subjects: 0
Study: 120339

Group type: EXPERIMENTAL
Intervention: AMCA (160 mg/extraction site)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: AMCA
Number of subjects: 120
Study: 31280035

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) combined with medication
Number of subjects: 124

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) alone
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 124
Study: 28043048

Group type: EXPERIMENTAL
Intervention: Combined IFG-IGT
Number of subjects: 7542

Group type: COMPARATOR
Intervention: Isolated IFG
Number of subjects: 7542

Group type: COMPARATOR
Intervention: Isolated IGT
Number of subjects: 7542

Group type: EXPERIMENTAL
Intervention: Age, urban residence, family history of diabetes, smoking status, abdominal obesity, hypertension, high triglycerides, low HDL cholesterols
Number of subjects: 7542
Study: 26410589

Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD) for 20 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Mediterranean Diet (MD) for 20 days
Number of subjects: 32
Study: 23224592

Group type: EXPERIMENTAL
Intervention: Parental state anxiety
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Parental trait anxiety
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Parental trait anxiety in treatment responders
Number of subjects: 30
Study: 21246185

Group type: EXPERIMENTAL
Intervention: High-protein diet (30% total energy, n = 53)
Number of subjects: 99

Group type: COMPARATOR
Intervention: High-carbohydrate diet (55% total energy, n = 46)
Number of subjects: 99
Study: 18471454

Group type: EXPERIMENTAL
Intervention: Niacin extended release plus simvastatin (NER/S) 1,000/20 mg/day
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Niacin extended release plus simvastatin (NER/S) 2,000/20 mg/day
Number of subjects: 319

Group type: COMPARATOR
Intervention: Simvastatin 20 mg/day
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Niacin extended release plus simvastatin (NER/S)
Number of subjects: 319
Study: 16936391

Group type: COMPARATOR
Intervention: Splinting (wearing splint in neutral position for 4 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral prednisolone 20 mg/day for 2 weeks followed by 10 mg/day for 2 weeks
Number of subjects: 40
Study: 14657842

Group type: EXPERIMENTAL
Intervention: Oral antihistamines
Number of subjects: 0
Study: 10690544

Group type: EXPERIMENTAL
Intervention: Pretreatment NSE levels
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Treatment-induced minimum NSE values
Number of subjects: 121

Group type: COMPARATOR
Intervention: Etoposide and cisplatin treatment (4 to 6 cycles)
Number of subjects: 121
Study: 9088679

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 50
Study: 1371938

Group type: EXPERIMENTAL
Intervention: Octreotide 5 micrograms/h
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Octreotide 20 micrograms/h
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Octreotide 80 micrograms/h
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Octreotide 5 micrograms/h with secretin and ceruletide
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Octreotide 20 micrograms/h with secretin and ceruletide
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Octreotide 80 micrograms/h with secretin and ceruletide
Number of subjects: 18
Study: 3884406

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg 3 times daily orally)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: COMPARATOR
Intervention: Metoclopramide and Placebo
Number of subjects: 25
Study: 29540420

Group type: EXPERIMENTAL
Intervention: New Orleans intervention model (NIM) - an infant mental health service
Number of subjects: 0

Group type: COMPARATOR
Intervention: Case management (CM) - enhanced social work services as usual
Number of subjects: 0
Study: 27094495

Group type: EXPERIMENTAL
Intervention: Neurodynamic mobilization group (manual therapy and neurodynamic techniques)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrophysical modalities group (red and infrared laser and ultrasound therapy)
Number of subjects: 0
Study: 24428467

Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg orally once daily) plus sofosbuvir (400 mg orally once daily) for 12 or 24 weeks, with or without ribavirin
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Daclatasvir plus sofosbuvir (with or without ribavirin)
Number of subjects: 211
Study: 22856376

Group type: COMPARATOR
Intervention: Brain training intervention over a 30-day period
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: MRI testing
Number of subjects: 1500
Study: 19847185

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC)
Number of subjects: 0
Study: 18408224

Group type: EXPERIMENTAL
Intervention: Bevacizumab + reduced-dose interferon (IFN) 6 or 3 MIU
Number of subjects: 649

Group type: COMPARATOR
Intervention: IFN + placebo
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Bevacizumab + reduced-dose IFN
Number of subjects: 649
Study: 16455029

Group type: EXPERIMENTAL
Intervention: Plain radiography
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: CT scans
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Scintigraphy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Biopsy
Number of subjects: 38
Study: 12354701

Group type: EXPERIMENTAL
Intervention: Brachial gradient present (Group 1)
Number of subjects: 228

Group type: COMPARATOR
Intervention: No brachial gradient (Group 2)
Number of subjects: 228
Study: 11279947

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg per day
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 8826574

Group type: EXPERIMENTAL
Intervention: Tranexamic acid administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 1874262

Group type: EXPERIMENTAL
Intervention: Rehabilitation programme (RP)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Counselling programme (CP)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Combined UC and CP
Number of subjects: 182
Study: 6617242

Group type: EXPERIMENTAL
Intervention: 2.5 mg indapamide + methyldopa (average 1100 mg daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 50 mg hydrochlorothiazide + methyldopa (average 1575 mg daily)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 2.5 mg indapamide (Step 1 medication only)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 2.5 mg indapamide (Step 1) and 50 mg hydrochlorothiazide (Step 1)
Number of subjects: 29
Study: 30919396

Group type: EXPERIMENTAL
Intervention: Parental perceptions of child weight status
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Parents of overweight children
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Child Feeding Questionnaire (CFQ) scores
Number of subjects: 331
Study: 31806127

Group type: COMPARATOR
Intervention: Conventional prophylactic antibiotic treatment
Number of subjects: 19603

Group type: COMPARATOR
Intervention: Incremental prophylactic antibiotic treatment
Number of subjects: 19603

Group type: EXPERIMENTAL
Intervention: PADIT risk score (0 to 15 points)
Number of subjects: 19603
Study: 29251978

Group type: EXPERIMENTAL
Intervention: Customized recommendations (CR) during Recovery Line calls
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Gain-frame and loss-frame reminder messages
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Short, immediate, and long-term message latency
Number of subjects: 127

Group type: COMPARATOR
Intervention: No recommendations on Recovery Line calls (Control)
Number of subjects: 127
Study: 26590381

Group type: EXPERIMENTAL
Intervention: Traditional monofilament sutures (Group 1)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Barbed knotless sutures (Group 2)
Number of subjects: 142
Study: 23990660

Group type: EXPERIMENTAL
Intervention: Self-management of hypertension
Number of subjects: 0
Study: 22315048

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (80 mg caffeine)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 24
Study: 19934295

Group type: EXPERIMENTAL
Intervention: Ipilimumab monotherapy
Number of subjects: 0
Study: 17161119

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 90 μg/ethinyl estradiol 20 μg daily for 1 year
Number of subjects: 146
Study: 15753500

Group type: EXPERIMENTAL
Intervention: Fast group (1 mL/sec)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Slow group (0.05 mL/sec)
Number of subjects: 40
Study: 12224975

Group type: EXPERIMENTAL
Intervention: 585-nm pulsed-dye laser (PDL) (5 J/cm(2))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide (TAC) (20 mg/mL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intralesional 5-fluorouracil (5-FU) (50 mg/mL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intralesional TAC (1 mg/mL) mixed with 5-FU (45 mg/mL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 10
Study: 9690971

Group type: EXPERIMENTAL
Intervention: Newer antipsychotic drugs (clozapine, risperidone, olanzapine, amisulpride, quetiapine, sertindole)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional antipsychotic drugs (haloperidol, chlorpromazine)
Number of subjects: 0
Study: 7750167

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chinese and western medicine treatments
Number of subjects: 0
Study: 3383542

Group type: EXPERIMENTAL
Intervention: minibag via gravity flow (MG)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: minibag with secondary infusion tubing below a volumetric infusion pump (MP)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: metered chamber via volumetric infusion pump (MC)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: syringe pump (SP)
Number of subjects: 11
Study: 31626568

Group type: COMPARATOR
Intervention: Action Observation (AO)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Motor Imagery (MI)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 45
Study: 29573038

Group type: EXPERIMENTAL
Intervention: Conditioned Pain Modulation (CPM)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Painful Cutaneous Electrical Stimulation (PCES) with constant current intensity
Number of subjects: 29

Group type: COMPARATOR
Intervention: Painful Cutaneous Electrical Stimulation (PCES) with variable intensities
Number of subjects: 29
Study: 28830365

Group type: EXPERIMENTAL
Intervention: Ringer's lactate infusion (25 ml/kg, approximately 2 l over 30 min)
Number of subjects: 7
Study: 23952181

Group type: EXPERIMENTAL
Intervention: Mydriatic drops (tropicamide 0.5% and phenylephrine 2.5%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (undilated pupils)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dilated pupils (with glaucoma)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dilated pupils (without glaucoma)
Number of subjects: 0
Study: 23325710

Group type: EXPERIMENTAL
Intervention: Intralesional injection of triamcinolone acetonide (TA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mouth rinse of triamcinolone acetonide (TA)
Number of subjects: 40
Study: 21830063

Group type: EXPERIMENTAL
Intervention: ivabradine (5-7.5 mg bid) plus bisoprolol 5 mg od
Number of subjects: 29

Group type: COMPARATOR
Intervention: bisoprolol uptitrated to 7.5 mg and then 10 mg od
Number of subjects: 29
Study: 18330518

Group type: EXPERIMENTAL
Intervention: Flat-panel volumetric CT (VCT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional CT (cCT)
Number of subjects: 22
Study: 17126776

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerine (3-in, 7.5 cm)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (3-in, 7.5 cm)
Number of subjects: 60
Study: 14506196

Group type: EXPERIMENTAL
Intervention: (131)I-trace-labeled BsMAb doses escalated from 10 to 100 mg/m(2)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 75 mg/m(2) BsMAb and 2.6-4.2 GBq of (131)I-hapten
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Reduction of BsMAb dose to 40 mg/m(2)
Number of subjects: 35

Group type: COMPARATOR
Intervention: (131)I-hapten
Number of subjects: 35
Study: 11374263

Group type: EXPERIMENTAL
Intervention: Full weight-bearing immediately after operation (Group A)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Weight-bearing after 6 weeks (Group B)
Number of subjects: 33
Study: 9916607

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg BID for 3 months
Number of subjects: 178

Group type: COMPARATOR
Intervention: Theophylline BID for 3 months
Number of subjects: 178
Study: 7914795

Group type: EXPERIMENTAL
Intervention: Ro 40-2148 (400 mg diluted in 100 ml water, twice a day for 14 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3196390

Group type: EXPERIMENTAL
Intervention: Emepronium 25 mg/kg p.o.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emepronium 50 mg/kg p.o.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emepronium 100 mg/kg p.o.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emepronium 200 mg q.i.d. in human volunteers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emepronium 400 mg q.i.d. in human volunteers
Number of subjects: 0
Study: 31301812

Group type: EXPERIMENTAL
Intervention: Malawi Trauma Score (MTS)
Number of subjects: 62354
Study: 28091393

Group type: EXPERIMENTAL
Intervention: rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF)
Number of subjects: 717

Group type: COMPARATOR
Intervention: efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF)
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 717
Study: 25272149

Group type: EXPERIMENTAL
Intervention: EPA-enriched n-3 1000 mg/d
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: DHA-enriched n-3 1000 mg/d
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 24235221

Group type: EXPERIMENTAL
Intervention: 0.9% Ca from HSC
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 0.6% Ca with phytase
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: HSC
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 0.9% Ca
Number of subjects: 240
Study: 21794155

Group type: EXPERIMENTAL
Intervention: Physician-based education and activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rehabilitation program developed by Aviva Canada
Number of subjects: 0

Group type: COMPARATOR
Intervention: Legislated standard of care (Pre-approved Framework Guideline for Whiplash)
Number of subjects: 0
Study: 19114888

Group type: EXPERIMENTAL
Intervention: ARG-enriched immune-enhancing diet (IED)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard formula (control group, n = 11)
Number of subjects: 22
Study: 16934909

Group type: EXPERIMENTAL
Intervention: SGN-15 200 mg/m2/week with docetaxel 35 mg/m2/week (Arm A)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Docetaxel 35 mg/m2/week alone (Arm B)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) analyses
Number of subjects: 62
Study: 15293486

Group type: EXPERIMENTAL
Intervention: Joint protection programme (educational-behavioural training)
Number of subjects: 127
Study: 11737115

Group type: COMPARATOR
Intervention: Palpation-guided biopsy (GI)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided biopsy (GII)
Number of subjects: 82
Study: 9266922

Group type: EXPERIMENTAL
Intervention: Intravenous iron (200 mg of iron sucrose)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Recombinant human erythropoietin (r‐HuEPO; 300 U/kg body weight) alone
Number of subjects: 7
Study: 8493761

Group type: EXPERIMENTAL
Intervention: Human interferon alpha (HuIFN‐alpha) administered orally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0